The Scottish Medicines Consortium (SMC) has recommended that Kesimpta can be prescribed for people with relapsing remitting MS who are having relapses or have MRI evidence of MS activity.
This is excellent news! The approval of Kesimpta in Scotland increases the choices for people with relapsing MS. An expanding range of drugs, working in different ways and with different benefits and risks, means more people can find the treatment that is best for them. Kesimpta offers access to an effective treatment which doesn’t require regular hospital visits.
- David Martin, Chief Executive Officer, MS Trust
NICE recommended Kesimpta for the NHS in England and Wales earlier this year.
In Northern Ireland, the Department of Health reviews NICE guidance for NHS use.
Kesimpta is self-injected under the skin once a month.
In clinical trials for relapsing MS, Kesimpta reduced the risk of relapse by 50-59% compared to Aubagio, reduced disability progression and the number of lesions seen on MRI scans.
Kesimpta binds to a marker (CD20) on the surface of B cells, a type of white blood cell (lymphocyte) which is thought to be involved when the immune system attacks the myelin coating of nerves. Targeted B cells are destroyed. Kesimpta works in similar way to Ocrevus (ocrelizumab).
In clinical trials, the most frequent side effects were injection-related reactions. Most of these were mild to moderate, cleared up the same or following day and were associated with the first Kesimpta injection; they were less frequent with subsequent injections. Other side effects that occurred in at least 10% of those taking Kesimpta were head colds, headache, chest infections and urinary tract infections.
New study provides strong evidence for role of Epstein Barr virus as a trigger for multiple sclerosis
14 Jan 2022 - 00:00
New research has provided evidence that infection with the Epstein Barr virus acts as a trigger for people to develop MS.
The PANORAMIC trial for Covid-19 treatment
23 Dec 2021 - 00:00
If you are not eligible to receive Covid-19 treatment automatically on the basis of increased risk, you may be able to get antiviral medication through the PANORAMIC clinical trial.
Ponvory (ponesimod) approved for relapsing remitting MS in England and Wales
23 Dec 2021 - 00:00
The MS Trust is delighted that Ponvory (ponesimod) has been approved in England and Wales for people with active relapsing remitting multiple sclerosis.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.